Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2011 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
Conference Journal of Clinical Oncology · March 1, 2026 476Background: Lack of standardized reporting and collection of patient-reported outc ... Full text CiteA randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.
Conference Journal of Clinical Oncology · March 1, 2026 Ipilimumab plus nivolumab (ipi/nivo) is a standard of care for treatment-naïve, metastatic clear cell renal cell carcinoma (ccRCC). While durability of response may be superior to combination therapy with PD-1 inhibitors and agent tyrosine kinase inhibitor ... Full text CiteClinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
Conference Journal of Clinical Oncology · March 1, 2026 228Background: Survival outcomes with sip-T in mCRPC are variable, and mechanisms dri ... Full text CiteRecent Grants
A Randomized Phase 2 Trial of Nivolumab, Relatlimab plus Ipilimumab vs. Nivolumab plus Ipilimumab in first-line advanced renal cell carcinoma (RCC)
Clinical TrialPrincipal Investigator · Awarded by The University of Texas MD Anderson Cancer Center · 2025 - 2030A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67CuSAR-BBN for identification and treatment of RPRexpressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA617
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2028View All Grants
Education
Tulane University ·
2004
M.D.